1 Classification

Antiemetic medications are grouped by the receptors or pathways they affect. This classification is useful because nausea and vomiting can arise from different triggers, and no single drug class is ideal for every situation. Some agents are selected for rapid relief, while others are preferred for prevention over longer periods. In practice, clinicians often choose a medication based on the suspected cause, the expected duration of symptoms, and the patient’s risk of adverse effects.

1.1 Serotonin receptor antagonists

Serotonin receptor antagonists, especially those targeting 5-HT3 receptors, are among the most widely used antiemetics. They are commonly prescribed for chemotherapy-induced nausea and vomiting, postoperative symptoms, and other settings where serotonin release contributes to emesis. These drugs are valued for their effectiveness and generally favorable tolerability, although headache, constipation, and occasional cardiac effects may occur.

1.2 Dopamine receptor antagonists

Dopamine receptor antagonists reduce nausea by blocking dopamine signaling involved in the vomiting reflex. Some agents in this group are also prokinetic, meaning they help increase gastrointestinal motility. They are used in various nausea syndromes, including migraine-associated nausea, gastroparesis-related symptoms, and postoperative settings. Their main limitations include sedation, movement disorders, and, in some cases, endocrine effects.

1.3 Histamine receptor antagonists

Histamine receptor antagonists are especially useful in motion sickness and vertigo-related nausea. By reducing vestibular input to the brain’s emetic pathways, they can lessen symptoms triggered by movement or inner ear disturbance. Drowsiness is a common effect, which can be helpful at night but limiting during daytime use.

1.4 Anticholinergic agents

Anticholinergic antiemetics interfere with muscarinic signaling, particularly within vestibular pathways. They are most often associated with motion sickness prevention. A well-known effect of this class is dry mouth, and other anticholinergic reactions may include blurred vision, urinary retention, and confusion, especially in older adults.

1.5 Neurokinin-1 receptor antagonists

Neurokinin-1 receptor antagonists block substance P, a neuropeptide involved in the vomiting cascade. They are often used as part of combination regimens for chemotherapy-related nausea and vomiting, particularly when prevention is important over multiple days. These agents can improve control when paired with serotonin antagonists and corticosteroids.

1.6 Cannabinoids

Cannabinoids may be used when standard therapies do not provide adequate relief, especially in chemotherapy-related nausea. They can also stimulate appetite in some patients. Their use is limited by psychoactive effects, dizziness, and variability in response. Because of these issues, they are usually reserved for selected cases.

1.7 Corticosteroids

Corticosteroids are frequently combined with other antiemetics rather than used alone. They can enhance antiemetic control in chemotherapy protocols and may also help reduce inflammation-related nausea in certain contexts. The exact mechanism is not fully defined, but their broad modulatory effects appear to contribute to symptom relief.

1.8 Benzodiazepines

Benzodiazepines are not primary antiemetics, but they can help when anxiety, anticipation, or conditioned responses worsen nausea. They are particularly useful for anticipatory nausea in oncology care. Their benefits are tied to anxiolysis and sedation, and their use requires caution because of dependence potential and cognitive impairment.

2 Mechanism of action

Antiemetics work by interrupting the signaling network that generates nausea and vomiting. The vomiting response is coordinated by the brainstem, but it receives input from the gastrointestinal tract, inner ear, bloodstream, and higher cortical centers. Different medications act at different points in this pathway, which explains why combinations are often more effective than single agents.

2.1 The vomiting center

The vomiting center is a functional network in the medulla that organizes the motor response of emesis. It integrates signals from multiple sources and activates diaphragmatic, abdominal, and gastric contractions that lead to vomiting. Antiemetic drugs may reduce the center’s responsiveness indirectly by blocking upstream neurotransmitters or directly by altering central signaling.

2.2 The chemoreceptor trigger zone

The chemoreceptor trigger zone, located near the area postrema, detects circulating toxins and drug signals in the blood and cerebrospinal fluid. Because this region is exposed to these substances more readily than much of the brain, it plays a major role in drug-induced nausea. Dopamine, serotonin, and neurokinin pathways are especially important here, making them key targets for antiemetic therapy.

2.3 Gastrointestinal signaling pathways

The gastrointestinal tract contributes to nausea through vagal and enteric nerve pathways. Irritation, delayed gastric emptying, inflammation, and distension can stimulate serotonin release from gut cells, which then activates afferent nerves to the brain. Some antiemetics act by reducing these peripheral signals, while others improve motility or dampen sensory transmission.

3 Clinical uses

Antiemetics are prescribed across many clinical settings because nausea and vomiting can result from illness, treatment, motion, or physiologic change. The choice of treatment depends on the likely trigger and whether the goal is prevention or rescue therapy. In many cases, supportive measures and hydration are also important.

3.1 Motion sickness

Motion sickness is a classic indication for antiemetic therapy. It results from conflicting sensory input between the vestibular system, vision, and proprioception. Antihistamines and anticholinergic agents are commonly used for prevention because they target vestibular pathways before symptoms begin.

3.2 Postoperative nausea and vomiting

Postoperative nausea and vomiting are common after anesthesia and surgery. Risk is influenced by patient characteristics, type of procedure, and anesthetic technique. Serotonin antagonists and other agents are often used prophylactically, especially in patients with a history of prior episodes or other risk factors.

3.3 Chemotherapy-induced nausea and vomiting

Chemotherapy can provoke both immediate and delayed nausea and vomiting through multiple biochemical pathways. Modern prevention strategies usually combine several drug classes to cover these mechanisms. The goal is not only symptom control but also improved treatment adherence and quality of life.

3.3.1 Acute prevention

Acute prevention focuses on symptoms that occur during or shortly after chemotherapy administration. Serotonin receptor antagonists, neurokinin-1 receptor antagonists, corticosteroids, and sometimes dopamine antagonists are used in combination. Regimens are selected according to the emetogenic potential of the chemotherapy agent.

3.3.2 Delayed prevention

Delayed prevention addresses symptoms that emerge hours to days after chemotherapy. Neurokinin-1 receptor antagonists and corticosteroids are especially important in this phase, often alongside other agents. Prevention is often continued after treatment because delayed nausea can be persistent and harder to manage once established.

Nausea and vomiting during pregnancy are common, especially in the first trimester. Management usually begins with dietary adjustments and nonpharmacologic measures, followed by medication when needed. Drug selection must consider maternal benefit and fetal safety, so therapies are chosen carefully and conservatively.

3.5 Gastroenteritis and other gastrointestinal disorders

Gastroenteritis, gastrointestinal irritation, and motility disorders can produce nausea and vomiting through local and systemic pathways. Antiemetics may be used to improve oral intake and reduce distress, particularly when dehydration is a concern. In some disorders, agents that promote gastric emptying may be useful alongside symptom control.

3.6 Vertigo-associated nausea

Vertigo can cause prominent nausea because vestibular signals strongly influence the emetic system. Histamine antagonists and anticholinergics are often used when symptoms are related to inner ear dysfunction or motion-like sensations. Treating the underlying vestibular disorder is also important for sustained improvement.

4 Administration and dosing

The route of administration depends on symptom severity, the ability to retain oral medication, and the expected duration of treatment. Some patients need a single preventive dose, while others require scheduled dosing over several days. In acute illness, rapid onset may be more important than convenience.

4.1 Oral formulations

Oral antiemetics are widely used for mild to moderate symptoms and for prevention in outpatient settings. They are convenient, inexpensive, and suitable when the patient can keep tablets or liquids down. Absorption may be limited during active vomiting, so oral therapy is less reliable in severe cases.

4.2 Injectable formulations

Injectable formulations are preferred when rapid action is needed or when oral intake is not possible. They are often used in emergency care, perioperative medicine, and oncology. Intravenous and intramuscular routes allow dependable delivery, though they may require monitoring for immediate adverse reactions.

4.3 Transdermal and rectal formulations

Transdermal and rectal options are useful when prolonged treatment is needed or swallowing is difficult. Transdermal systems provide steady absorption over time, while rectal preparations can be helpful when vomiting prevents oral dosing. These routes are practical in selected patients, though onset may be slower than with injections.

4.4 Combination therapy

Combination therapy is common because different drugs address different pathways in the vomiting reflex. This approach is especially important in chemotherapy and postoperative care, where multiple triggers may be active at once. Using more than one class can improve efficacy while allowing lower doses of individual agents.

5 Adverse effects

Adverse effects vary by drug class, dose, route, and duration of use. Some reactions are predictable extensions of the medication’s mechanism, while others reflect off-target effects. Careful selection and monitoring help reduce unnecessary discomfort and serious complications.

5.1 Sedation

Sedation is common with several antiemetics, particularly antihistamines, anticholinergics, and benzodiazepines. It may be useful when rest is desirable but can interfere with driving, work, or alertness. Additive drowsiness may occur when these drugs are combined with alcohol, opioids, or other central nervous system depressants.

5.2 Extrapyramidal symptoms

Extrapyramidal symptoms can occur with dopamine receptor antagonists. These reactions may include dystonia, akathisia, tremor, and parkinsonian features. They are more likely with certain agents and higher doses, and they can be distressing even when transient. Prompt recognition is important because symptoms are often reversible.

5.3 Anticholinergic effects

Anticholinergic effects include dry mouth, constipation, blurred vision, urinary retention, and confusion. These reactions are most notable with anticholinergic antiemetics and some antihistamines. Older adults are more vulnerable, particularly when multiple medications with similar effects are used together.

5.4 Cardiac effects

Some antiemetics can affect cardiac conduction or rhythm. QT interval prolongation is a recognized concern with certain serotonin antagonists and other agents. The clinical significance depends on dose, underlying heart disease, electrolyte balance, and concurrent medications. Risk assessment is important in patients receiving multiple drugs.

5.5 Drug interactions

Antiemetics may interact with sedatives, antidepressants, antipsychotics, opioids, and medications that influence liver enzymes or cardiac conduction. These interactions can increase sedation, alter effectiveness, or raise the risk of adverse reactions. Review of the full medication list is an important part of prescribing.

6 Contraindications and precautions

Contraindications differ among drug classes, but all antiemetics require attention to patient-specific risk factors. Clinicians consider age, pregnancy status, organ function, and current medications before choosing therapy. In some cases, a safer alternative within the same general category may be available.

Children and older adults may respond differently to antiemetics. Pediatric dosing requires careful calculation and attention to formulation, while older adults are more susceptible to sedation, confusion, and anticholinergic toxicity. Because of these differences, dose selection and monitoring are especially important at the extremes of age.

6.2 Pregnancy and lactation

During pregnancy and breastfeeding, medication choice must balance symptom relief with safety. Some antiemetics have a longer record of use in these settings than others. Decisions are often individualized according to severity, trimester, and available non-drug measures.

6.3 Hepatic and renal impairment

Liver and kidney dysfunction can alter drug metabolism and elimination. As a result, standard doses may produce stronger or longer-lasting effects, increasing the chance of adverse events. Dose adjustment or avoidance may be necessary depending on the agent and the degree of impairment.

7 Special populations

Certain patient groups need tailored antiemetic strategies because their symptoms, risks, or treatment goals differ from the general population. In these settings, the balance between benefit and side effects is often narrower, making individualized care especially important.

7.1 Pediatric use

In children, nausea may be harder to assess because symptoms are not always expressed clearly. Dosage must be based on age and weight, and some medications are unsuitable for young patients. Preventing dehydration is a major concern, particularly when vomiting is caused by infection or gastrointestinal illness.

7.2 Geriatric use

Older adults are at higher risk of dizziness, falls, confusion, and drug accumulation. They may also take multiple medications that interact with antiemetics. For this reason, lower starting doses and close observation are often appropriate.

7.3 Oncology patients

Patients receiving cancer treatment frequently need multi-drug antiemetic regimens. Therapy is often planned in advance to match the emetogenicity of the treatment protocol. Effective control supports nutrition, hydration, and the ability to continue anticancer therapy as scheduled.

7.4 Palliative care

In palliative care, antiemetics are used to improve comfort and reduce distress from advanced illness. Causes of nausea may include medications, bowel obstruction, metabolic changes, and central nervous system involvement. Treatment is usually symptom-focused and may involve trial of different classes based on the suspected mechanism.

8 History

The history of antiemetic therapy reflects progress in pharmacology, physiology, and supportive medicine. Early treatments were often nonspecific, while later developments targeted defined receptor systems and improved predictability. As medical care expanded, control of nausea became an important part of surgery, oncology, and outpatient treatment.

8.1 Development of early antiemetics

Early antiemetics included broadly acting sedatives, antihistamines, and other compounds that offered partial relief but often caused substantial drowsiness or anticholinergic burden. These medications laid the groundwork for later discovery of more selective therapies. Their use also helped clarify the role of vestibular and central pathways in vomiting.

8.2 Advances in modern antiemetic therapy

Modern antiemetic therapy advanced with the identification of serotonin, dopamine, and substance P pathways in emesis. The development of receptor-specific drugs improved symptom prevention, especially in chemotherapy and surgery. Combination regimens became standard for many high-risk situations, reflecting a more precise understanding of the vomiting reflex.